Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
|23 Jul 2021||$5.27||$-0.08||-1.50%||386,705||$5.45||$5.46||$5.18|
|22 Jul 2021||$5.35||$0.15||2.88%||162,235||$5.22||$5.40||$5.15|
|21 Jul 2021||$5.20||$-0.15||-2.80%||326,296||$5.50||$5.50||$5.17|
|20 Jul 2021||$5.35||$0.28||5.52%||446,162||$5.10||$5.36||$5.08|
|19 Jul 2021||$5.07||$-0.13||-2.50%||607,727||$5.20||$5.21||$4.99|
|16 Jul 2021||$5.20||$-0.03||-0.57%||315,018||$5.21||$5.21||$5.11|
|15 Jul 2021||$5.23||$-0.10||-1.88%||455,014||$5.40||$5.41||$5.21|
|14 Jul 2021||$5.33||$0.01||0.19%||444,509||$5.34||$5.49||$5.30|
|13 Jul 2021||$5.32||$-0.29||-5.17%||421,434||$5.61||$5.61||$5.32|
|12 Jul 2021||$5.61||$0.06||1.08%||369,914||$5.56||$5.61||$5.44|
|09 Jul 2021||$5.55||$-0.07||-1.25%||256,876||$5.65||$5.69||$5.43|
|08 Jul 2021||$5.62||$-0.09||-1.58%||591,308||$5.88||$5.88||$5.50|
|07 Jul 2021||$5.71||$0.17||3.07%||297,395||$5.62||$5.75||$5.55|
|06 Jul 2021||$5.54||$-0.19||-3.32%||373,461||$5.73||$5.75||$5.45|
|05 Jul 2021||$5.73||$-0.08||-1.38%||212,747||$5.76||$5.83||$5.61|
|02 Jul 2021||$5.81||$-0.10||-1.69%||326,852||$5.96||$5.98||$5.77|
|01 Jul 2021||$5.91||$-0.18||-2.96%||367,807||$6.15||$6.15||$5.83|
|30 Jun 2021||$6.09||$0.24||4.10%||552,406||$6.05||$6.20||$5.99|
|29 Jun 2021||$5.85||$-0.07||-1.18%||481,768||$5.93||$5.98||$5.75|
|28 Jun 2021||$5.92||$-0.45||-7.06%||920,348||$6.36||$6.47||$5.84|
|25 Jun 2021||$6.37||$0.74||13.14%||1,901,497||$5.95||$6.65||$5.84|
|12 May 2021||Christian Behrenbruch||Issued||100||$373,626||
Issue of options.
|02 Nov 2020||Oliver Buck||Exercise||165||$140,530||
Exercise of options.
|02 Nov 2020||Oliver Buck||Buy||165||$140,530||
Exercise of options.
|Mr Harry Kevin McCann||Non-Executive ChairmanNon-Executive Director||Sep 2017||
Mr McCann is Chairman of China Matters. He is a Member of Champions of Change, a ProChancellor of the University of Sydney, a Trustee of the Sydney Opera House Trust and a Director of E&P Financial Services Group. Previously, he has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited and ING Management Limited. He practiced as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He is a member of the Risk Committee.
|Ms Jann E Skinner||Non-Executive Director||Jun 2018||
Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She is an independent non-executive director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk & Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. She is a member of the Risk Committee.
|Dr Christian Peter Behrenbruch||Chief Executive OfficerManaging Director||Jan 2017||
Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre).
|Dr Andreas Kluge||Non-Executive Director||Jan 2017||
Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO, a full service CRO for Phase I-III biological, radiopharmaceutical and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH (www.abx.de). He is further Founder, General Manager and Medical Director for Therapeia, an early stage development company in the field of neurooncology, which was acquired by Telix. He has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices. He is the author of range of patents and publications in the field of Nuclear Medicine, neurology, infection and immunology.
|Mr Oliver Buck||Non-Executive Director||Jan 2017||
Mr Buck has spent his professional career in a range of entrepreneurial and management positions in industrial companies. He has served as founder and Managing Director of range of companies in the fields of manufacturing, technology, demilitarisation, pharmaceuticals and information technologies. He is the co-founder of ITM Isotopen Technologien Munchen AG. Since 2012, he has acted as senior advisor to the CEO in a role that continues to support the ITM group as it has become a leader in next generation medical isotopes and theranostics. He is a member of the Risk Committee.
|Dr Mark Alexander Nelson||Non-Executive Director||Sep 2017||
Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. He is Chairman of Art Exhibitions Australia, a Director of Kaldor Public Art Projects, Director of The Mindgardens Neuroscience Network, and serves as a Governor of the Florey Neurosciences Institute. Previously he was a Director of The Howard Florey Institute of Experimental Physiology and Medicine, and served on the Commercialisation Committee of the Florey Institute. He is a member of the Risk Committee.
|Ms Melanie Farris||Chief Governance & Risk OfficerCompany Secretary||Mar 2017||
|David Cade||Chief Business Officer & Head of Investor Relations||
|Melanie Farris||Chief Governance & Risk OfficerCompany Secretary||
|Colin Hayward||Chief Medical Officer||
|Jonathan Barlow||General Counsel||
|Margaret Haarhoff||Global Director of People & Culture||
|Michael Larcom||Global Director of Quality||
|Doug Cubbin||Group Chief Financial Officer||
|Gabriel Liberatore||Group Chief Operating Officer||
|Ludovic Wouters||President Telix Europe||
|Shintaro Nishimura||President Telix Japan||
|Bernard Lambert||President Telix US||
|Tracey Brown||SVP Global Clinical Operations||
|Sunil Kadam||SVP Global Regulatory Affairs||
|HSBC Custody Nominees (Australia) Limited||37,477,609||13.37%|
|ELK River Holdings Pty Ltd||24,675,000||8.80%|
|Gnosis Verwaltungsgesellschaftm B H||24,675,000||8.80%|
|Grand Decade Developments Limited||20,947,181||7.47%|
|J P Morgan Nominees Australia Pty Limited||8,371,563||2.99%|
|UV Cap Gmbh & Co Kg||7,775,000||2.77%|
|BNP Paribas Noms Pty Ltd||6,904,087||2.46%|
|The Oncidium Foundation||6,470,392||2.31%|
|National Nominees Limited||6,361,306||2.27%|
|Citicorp Nominees Pty Limited||6,249,988||2.23%|
|Scintec Diagnostics Gmbh||4,312,151||1.54%|
|BNP Paribas Nominees Pty Ltd||3,782,218||1.35%|
|UBS Nominees Pty Ltd||3,029,153||1.08%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,843,462||1.01%|
|Jean Marc Le Doussal||2,750,000||0.98%|
|Yelwac Pty Ltd||2,381,804||0.85%|
|Man Holdings Pty Ltd||2,238,750||0.80%|
|Telix Pharmaceuticals (Est) Pty Ltd||2,115,000||0.75%|
|Aglub Investments Pty Ltd||1,933,342||0.69%|
|Jean Francois Chatal||1,797,795||0.64%|